TPR100 is partnered for manufacturing and distribution in the UK with Thornton & Ross, one of the UK’s largest consumer healthcare companies and a subsidiary of STADA AG. In February 2019, the UK Medicines and Healthcare products Regulatory Agency (MHRA) responded to Thornton & Ross’s marketing authorisation application filed in July 2018, with a number of questions requiring additional laboratory work specifically around the permeation characteristics of TPR100 to be conducted. This further laboratory work is now complete. In conjunction with its commercial partner, Futura is seeking a scientific advisory meeting with the MHRA before the end of 2020 to review the data and provide regulatory clarity around the exact pathway for approval and any outstanding additional requirements. Futura is awaiting regulatory authorisation in the UK before progressing further with licensing discussions for further regions.